Skip to main content
. Author manuscript; available in PMC: 2020 Sep 24.
Published in final edited form as: Eur Urol. 2019 Feb 26;76(1):43–51. doi: 10.1016/j.eururo.2019.02.009

Table 1 –

Characteristics of the study overall and by centre

Belgium Finland Italy The Netherlands Spain Sweden Switzerland Total (excl. France) France, Herault France, Tarn Total
Age at randomisation, (yr), median (IQR) 63 (60.2, 66.2) 59 (54.8, 62.7) 62 (58.4, 65.9) 62 (58.0, 65.6) 60 (57.4, 64.2) 60 (57.2, 62.4) 61 (57.8, 65.1) 60 (57.1, 64.2) 62 (58.8, 65.9) 62 (57.9, 66.1) 61 (57.9, 65.0)
Randomised (n) 8562 80 379 14 515 34 833 2197 11 852 9903 162 241 57 643 21 350 241 234
Screening, n (%) 4307 (50%) 31 970 (40%) 7265 (50%) 17 443 (50%) 1056 (48%) 5901 (50%) 4948 (50%) 72 890 (45%) 28 784 (50%) 10 879 (51%) 112 553 (47%)
Control, n (%) 4255 (50%) 48 409 (60%) 7250 (50%) 17 390 (50%) 1141 (52%) 5951 (50%) 4955 (50%) 89 351 (55%) 28 859 (50%) 10 471 (49%) 128 681 (53%)
Follow-up (yr), median (IQR) 16 (11.1, 16.0) 16 (13.8, 16.0) 15 (13.2, 16.0) 16 (13.8, 16.0) 16 (15.1, 15.9) 16 (13.9, 16.0) 13 (11.6, 14.2) 16 (13.0, 16.0) 9 (8.9, 9.6) 11 (9.8, 10.5) 13 (9.5, 16.0)
Screened at least once, n (%) 3908 (91%) 23 771 (74%) 5730 (79%) 16 502 (95%) 1056 (100%) 4484 (76%) 4810 (97%) 60 261 (83%) 8121 (28%) 4143 (38%) 72 525 (64%)
Screening tests done (n) 6446 52 142 12 731 40 358 1846 15 475 12 068 141 066 10 060 5358 156 484
Screening rounds per man (mean) 1.5 1.6 1.8 2.3 1.7 2.6 2.4 1.9 0.3 0.5 1.4
Positive tests (n) 1058 5925 1443 9552 354 2896 2599 23 827 1627 821 26 275
Men with positive tests, n (%) 914 (21%) 4635 (14%) 1054 (15%) 6793 (39%) 326 (31%) 1537 (26%) 1729 (35%) 16 988 (23%) 1560 (5%) 760 (7%) 19 308 (17%)
Biopsies (n) 752 5404 902 8541 263 2509 2027 20 398 468 418 21 284
Biopsies/positive tests (%) 71.1 91.2 62.5 89.4 74.3 86.6 78.0 85.6 28.8 50.9 81.0
Men with biopsy at least once, n (%) 684 (75%) 4336 (94%) 741 (70%) 6187 (91%) 244 (75%) 1430 (93%) 1494 (86%) 15 116 (89%) 468 (30%) 410 (54%) 15 994 (83%)
Prostate cancer cases, screening group
 Prostate cancer cases overall in screening group, total (n) 482 3500 560 2376 92 814 620 8444 1718 747 10 909
 Screen-detected cancers (n) 188 1632 197 1868 60 576 436 4957 229 128 5314
 Interval cancers and cancers among nonattendees (n) 294 1868 363 508 32 238 184 3487 1489 619 5595
 Screen-detected cancers/biopsy (%) 25.0 30.2 21.8 21.9 22.8 23.0 21.5 24.3 48.9 30.6 25.0
 Cumulative incidence in screening group (%) a 11.2 11.0 8.0 13.6 8.7 13.8 12.6 11.7 6.0 6.9 9.8
Prostate cancer cases, control group
 Prostate cancer cases overall in control cohort, total (n) 393 4546 452 1325 60 592 364 7732 1541 690 9963
 Cumulative incidence in control group (%) a 9.2 9.4 6.5 7.6 5.3 9.9 7.4 8.7 5.4 6.6 7.8

IQR = interquartile range; PCa = prostate cancer.

a

Calculated as total cases/randomised, excluding patients with PCa before randomisation.